Argenx to Present at Upcoming Investor Conferences
Argenx to Present at Upcoming Investor Conferences
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on LinkedIn, X/Twitter, Instagram, Facebook, and YouTube.November 26, 2024
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in December.
2024年11月26日
荷兰阿姆斯特丹 - 全球免疫学公司和纳斯达克（ARGX）的argenx致力于改善患有严重自身免疫疾病的患者的生活，今天宣布管理团队成员将参加12月份以下即将举行的投资者会议。
-
Citi's 2024 Global Healthcare Conference. Fireside chat on Tuesday, December 3 at 1:45 p.m. ET in Miami, FL.
-
7th Annual Evercore I&I HealthCONx Conference. Fireside chat on Wednesday, December 4 at 1:45 p.m. ET in Coral Gables, FL.
-
Piper Sandler's 35th Annual Healthcare Conference. Fireside chat on Thursday, December 5 at 9:00 a.m. ET in New York, NY.
- 花旗银行2024年全球医疗保健会议。12月3日（星期二）下午1:45在佛罗里达州迈阿密举行炉边聊天。
- 第七届Evercore I&I健康会议。12月4日（星期三）下午1:45在佛罗里达州科勒尔盖布尔举行炉边聊天。
- Piper Sandler第35届年度医疗保健会议。12月5日（星期四）上午9:00在纽约纽约市举行炉边聊天。
Additional information regarding these events will be available on the Investors section of the argenx website at argenx.com/investors.
有关这些活动的更多信息将在argenx网站的投资者部分argenx.com/investors上提供。
About argenx
关于argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on LinkedIn, X/Twitter, Instagram, Facebook, and YouTube.
argenx是一家全球免疫学公司，致力于改善患有严重自身免疫性疾病的人们的生活。通过其免疫学创新计划（IIP）与领先的学术研究人员合作，argenx旨在将免疫学突破转化为世界一流的新型抗体药物组合。argenx开发并在美国、日本、以色列、欧盟、英国、中国和加拿大全球商业化了首个获批的新生儿Fc受体（FcRn）阻断剂。该公司正在评估efgartigimod在多种严重自身免疫性疾病中的应用，并在其治疗特定领域推进几种较早期的实验性药物。欲了解更多信息，请访问并关注我们的领英、推特、Instagram、Facebook和YouTube账号。
For further information, please contact:
如需更多信息，请联系：
Media:
媒体:
Ben Petok
bpetok@argenx.com
Ben Petok
bpetok@argenx.com
Investors:
投资者:
Alexandra Roy (US)
aroy@argenx.com
Alexandra Roy（美国）
aroy@argenx.com
Lynn Elton (EU)
lelton@argenx.com
Lynn Elton（欧盟）
lelton@argenx.com
译文内容由第三方软件翻译。
